Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors  by Moore, Laura Jeffords et al.
www.transonc.com
Trans la t iona l Onco logy Volume 9 Number 4 August 2016 pp. 295–305 295Antibody-Guided In Vivo
Imaging for Early Detection of
Mammary Gland Tumors1,2Laura Jeffords Moore*, Lopamudra Das Roy*, †,
Ru Zhou*, Priyanka Grover*, Shu-ta Wu*,
Jennifer M. Curry*, Lloye M. Dillon*, †,
Priya M. Puri*, Mahboubeh Yazdanifar*,
Rahul Puri†, Pinku Mukherjee*, † and Didier Dréau*
*Department of Biological Sciences, University of North
Carolina at Charlotte, 9201 University City Blvd., Charlotte,
NC 28223 USA; †OncoTAb, Inc., 243 Bioinformatics, 9201
University City Blvd., Charlotte, NC 28223, USAAbstract
BACKGROUND: Earlier detection of transformed cells using target-specific imaging techniques holds great
promise. We have developed TAB 004, a monoclonal antibody highly specific to a protein sequence accessible in
the tumor form of MUC1 (tMUC1). We present data assessing both the specificity and sensitivity of TAB 004
in vitro and in genetically engineered mice in vivo.METHODS: Polyoma Middle T Antigen mice were crossed to the
human MUC1.Tg mice to generate MMT mice. In MMT mice, mammary gland hyperplasia is observed between 6
and 10 weeks of age that progresses to ductal carcinoma in situ by 12 to 14 weeks and adenocarcinoma by 18 to
24 weeks. Approximately 40% of these mice develop metastasis to the lung and other organs with a tumor
evolution that closely mimics human breast cancer progression. Tumor progression was monitored in MMT mice
(from ages 8 to 22 weeks) by in vivo imaging following retro-orbital injections of the TAB 004 conjugated to
indocyanine green (TAB-ICG). At euthanasia, mammary gland tumors and normal epithelial tissues were collected
for further analyses. RESULTS: In vivo imaging following TAB-ICG injection permitted significantly earlier detection
of tumors compared with physical examination. Furthermore, TAB-ICG administration in MMT mice enabled the
detection of lung metastases while sparing recognition of normal epithelia. CONCLUSIONS: The data highlight the
specificity and the sensitivity of the TAB 004 antibody in differentiating normal versus tumor form of MUC1 and its
utility as a targeted imaging agent for early detection, tumor monitoring response, as well as potential clinical use
for targeted drug delivery.
Translational Oncology (2016) 9, 295–305Address all correspondence to: Didier Dréau, PhD, Department of Biological Sciences
and Center for Engineering and Biological Sciences, University of North Carolina at
Charlotte, 9201 University City Blvd., Charlotte, NC 28223 USA.
E-mail: ddreau@uncc.edu
1Funding: Supported in part through a grant from the North Carolina Biotechnology
Center. The funding sources had no involvement in study design; in the collection,
analysis, and interpretation of data; in the writing of the report; or in the decision to
submit the article for publication.
2Conflict of interest: Drs. Rahul Puri, Pinku Mukherjee, Lopamudra das Roy, and Lloye
Dillon are, respectively, CEO,CSO, and employees ofOncoTAb Inc., a startup company that
own patents and rights to the TAB 004 antibody. Other authors declare no conflict of interest.
Received 26 February 2016; Revised 28 April 2016; Accepted 2 May 2016
© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
access articleunder theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1936-5233/16
http://dx.doi.org/10.1016/j.tranon.2016.05.001Introduction
In the past decade, survival of patients with breast cancer has
improved [1–3]. Routine mammograms and other screening
approaches have been associated with early detection of breast
cancers [4,5]. However, the repeated use of mammograms is not
without risk [4], and clinical guidelines remain highly debated [4].
Chiefly, mammograms overall miss 25% of tumors and up to 50% of
the tumors in late-stage diagnosis of women with extremely dense
breasts [4,6–8], resulting in late stage diagnosis. It is becoming clear
that cancer cells undergo specific molecular transformations long
before there is a detectable change in tumor morphology. The ability
to detect at these earliest stages of molecular dysregulation, before any
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intervention. Thus, the concept of molecularly targeted diagnostic
approaches would be very valuable.
MUC1 is a conserved transmembrane protein with an extensive
extracellular domain composed of repeated glycosylated peptide
motifs [9,10]. In tumor cells including breast tumors, these motifs are
hypoglycosylated and the MUC1 distribution is altered [11–13]. In
addition, as early as hyperplasia stages, the distribution and
glycosylation of MUC1 are altered and the cell-cell organization
disrupted [12,14]. As such, MUC1 is viewed as a key therapeutic
target in patients with breast cancer [15,16]. In breast cancers,
presence of circulatory MUC1 is associated with cancer progression
and can be monitored through detection of MUC1 (CA-15-3
antigen) circulatory concentrations [17–19]. However, CA-15-3 tests
rely mostly on the tumor burden and shed MUC1 and lack the
specificity to identify hypoglycosylated MUC1, a hallmark of breast
cancer progression. We have developed a new antibody that
specifically detects altered hypoglycosylated form of MUC1
(tMUC1): TAB 004 (OncoTAb, Inc., Charlotte, NC) [20].
Breast cancer progression is uniquely modeled in the
immune-competent spontaneous murine MMT model [10,21].
Derived from the PyMT model of spontaneous breast cancer and
genetically engineered to express the human form of hypoglycosylated
mucin-1 (tMUC1), the MMT mice develop spontaneous mammary
gland tumors expressing the human form of tMUC1 [10]. In those
mice, as in the parental PyMT mice, mammary gland hyperplasia is
observed between 6 and 10 weeks of age that progresses to ductal
carcinoma in situ by 12 to 14 weeks and adenocarcinoma by 18 to 24
weeks, and approximately 40% of the mice develop metastasis to the
lung and other organs [10]. In MMT mice, mammary tumor
evolution closely mimics human breast cancer progression. The
tumors are basal in cell origin and Her-2+ subtype [10].
Here we investigated the specificity and sensitivity of TAB 004 for
the early detection and monitoring of mammary tumor progression in
the MMT mice. Results indicate that TAB 004 specifically
immunoreacts with human tMUC1 and, when conjugated to an
imaging agent, indocyanine green (ICG), allows the early detection




TAB 004 was graciously provided for the study by OncoTAb Inc.
Conjugation kits to derive biotin-conjugated, horseradish peroxidase
(HRP)–conjugated, and ICG-conjugated TAB 004 were obtained
from Dojindo Molecular Technologies, Inc. (Rockville, MD) and
used according to manufacturers’ recommendations.
Generation of TAB 004 Antibody
Briefly, TAB 004 antibody (patent #US-2011-0123442, PCT/
US2011/037972) is a mouse IgG1 monoclonal antibody obtained
through the hybridoma approach and selected for its specific binding to
extracellular repeated sequences of tumor associated MUC1 altered, i.e.,
hypoglycosylated MUC1 protein specifically the TAPPA sequence and
the specific epitope (STAPPVHNV) [20]. The production of TAB 004 is
currently conducted in batches of antibody rigorously assayed for
consistent binding, stability, and purity (Supplemental Figure 1S, A–C;
LakePharma Inc., Belmont, CA).Cells and In Vitro Cultures
Murine cells PyMT and MMT were derived as described
previously [10]. The PyMT cell line was derived from PyMT
tumor, and the MMT cell line was obtained by stably expressing
full-length MUC1 in PyMT cells. Both cell lines were derived in Dr.
Mukherjee’s laboratory originally in 1998 and stored in multiple vials
in liquid nitrogen. Cells were authenticated by polymerase chain
reaction for specific DNA signatures for the polyoma middle T
antigen; the MMTV promoter; and, for MMT cells, the human
MUC1 gene. Additionally, in MMT cells, the cell surface expression
of human MUC1 was also assessed by Western blot (WB) and flow
cytometry. For this study, the PyMT and MMT cells used were
authenticated using the characterization methods described above
within 6 to 12 months of their use. All cells used either to generate
lysates or for cytometry investigations were cultured in sterile
conditions in Dulbecco’s modified Eagle’s medium in the presence
of antibiotics and antifungals supplemented with FBS and incubated
at 37°C, N90% humidity, and 5% CO2 conditions.
Orthotopic Mammary Tumor Model
MMT cells were implanted in the mammary pad of C57bl/6 6- to
8-week-old female mice, and the tumor growth was monitored using
both physical examination including caliper to measure tumor growth
and fluorescent monitoring as described for MMT spontaneous
tumor model (see below). Controls included mice similarly implanted
with PyMT cells. Furthermore, the route of injection of TAB 004 was
assessed in the orthotopic model. Briefly, C57bl/6 mice implanted
orthotopically with MMT tumor cells were injected 2 to 3 weeks
post–tumor implantation with either saline (vehicle control) or
intratumorally, intravenously, or intraperitoneally with TAB 004
conjugated with biotin, and tissues including tumor, spleen, kidneys,
liver, and lungs were collected 24 hours later. Tissues were fixed and
embedded in paraffin, and the presence of biotin-conjugated TAB
004 in the different tissues was assessed following incubation with
streptavidin-HRP and 3,3'-diaminobenzidine (DAB). As shown in
Figure 2S, in the absence of antibody, no HRP activity was detected.
HRP activity associated with the HRP-conjugated TAB 004 antibody
was faintly, highly, and strongly detected in tumor following
intratumoral, intravenous, and intraperitoneal injections, respectively.
With the exception of the spleen, in animals administered
biotin-conjugated TAB 004 intravenously, no other organ exhibited an
HRP activity associated with the HRP-conjugated TAB 004 antibody.
Specificity and Sensitivity of TAB 004 Antibody
The presence of altered MUC-1 was also determined by flow
cytometry and WB on PyMT and MMT murine cells using TAB
004. Briefly, for flow cytometry analyses, cells were grown in culture
conditions described above; detached from vessels; and, following a
blocking step incubated with TAB 004 antibody (30 minutes) and
after a secondary antibody stain (15 minutes), run on a Fortessa flow
cytometer (BD-Biosciences, San Jose, CA). Raw data were further
analyzed using FlowJo Software (Ashland, OR). Data are presented as
histogram with information on mean fluorescence intensity and
percentage of positive cells along with controls. Additionally, PyMT
and MMT cell lysates and MMT tumor mass lysates were assessed by
WBs. Briefly, lysates were obtained from cell cultured as described
above and fromMMT tumors through incubation with lysis buffer as
described previously [22,23]. Cell lysates were stored at −80°C until
use. Following electrophoresis in reducing conditions and transfer to
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was determined using TAB 004 antibody (overnight, 4°C) and
revealed using ECL reagent (ThermoFisher Scientific, Waltham,
MA). β-Actin was used as the loading control.
Monitoring Mammary Tumor Growth in the MMT
Spontaneous Murine Model
All mice were monitored and followed in accordance with the
University of North Carolina at Charlotte Institutional Animal Care and
Use Committee–approved protocol.MMTmice were genetically derived
from PyMT mice (C57BL/6 background) that spontaneously develop
mammary tumors and specifically express MUC1 [10]. Spontaneous
tumor progression follows a similar time line in PyMT andMMT female
mice. Frompuberty (6-8weeks old) onward,mammary tissues expressing
the polyomamiddle T antigen driven by theMMTVpromoter mimic all
the steps of breast cancer progression in humans including hyperplasia,
ductal carcinoma in situ, invasive carcinoma, and metastasis [10] at any
given time from 8 up to 22 to 24 weeks of age. Furthermore, multiple
tumor masses at different stages are present in this spontaneous model of
breast cancer progression. This murine model is aggressive as most
animals (N95%) develop multiple mammary tumor lesions which are
usually palpable by 14 to 16 weeks of age [10]. The main difference in
tumor progression between PyMT and MMT mice is the expression of
murine and human MUC1 glycoprotein, respectively [10].
Here, MMT mice were monitored in vivo for tumor progression
using the in vivo imaging system (IVIS; Perkin Elmer, Waltham,
MA). Both C57Bl/6 and PyMT mice were used as controls. In vivo
monitoring was conducted according to manufacturer’s recommen-
dations, following injections of TAB 004 conjugated with the
fluorophore indocyanine green (TAB-ICG). ICG has been shown to
have no significant side effects and is currently FDA-approved for
multiple procedures including angiography [24]. Before each imaging
sequence, TAB-ICG in sterile saline was administered retro-orbitally
or intraperitoneally to mice, and imaging was conducted 0.5, 4, 24,
and 48 hours postinjection. Animals were injected and imaged every 2
weeks for tumor progression. Tumor fluorescence was analyzed using
the Life Science Software Suite (Perkin Elmer), and region of interest
was defined at tumor location. In parallel, the presence of tumor
masses was assessed by palpation and recorded. Additionally, after
mouse euthanasia, further analyses of tumors (T) and specific organs
including mammary pads (MP), liver (Li), lungs (Lu), spleen (S), and
kidneys (K) were conducted ex vivo using the IVIS system and by
histology and immunohistochemistry (IHC; see below).
MMT spontaneous mammary tumor growth was also monitored
over time for gross pathology, cellular morphology, and the presence
of specific markers including tMUC1 using IHC with TAB 004
antibody (see below).
Monitoring Mammary Tumor Lung Metastases in the MMT
Spontaneous Murine Model
In the PyMT and MMT mouse models, early metastases, which
occur in the lungs, is masked in vivo by the fluorescence emitted by
larger tumors. Therefore, ex vivo analyses of organs isolated
posteuthanasia were conducted using the IVIS system. The
fluorescence signal (expressed as fluorescence units) was normalized
to the background fluorescence generated by each organ specifically
the lung, liver, spleen, and brain from control MMT mice (i.e.,
MMT mice not injected with TAB-ICG). Additionally, the presence
of lung metastases was determined following fixation, embedding,and sectioning of the lungs of MMT mice. Briefly, lungs from
animals 16 weeks or older were collected 24 hours postinjections and
embedded in paraffin. Five- to six-micrometer–thick sections were
obtained, stained with hematoxylin and eosin (H&E), and examined
for the presence of metastases.
Detection of tMUC1 by IHC
The expression of human altered MUC1 (tMUC1) was
determined in murine tumors using TAB 004. Murine tumors
from PyMT and MMT mice and normal mammary gland from
C57bl/6 mice were collected. Samples were fixed in buffered formalin
and embedded in paraffin, and 5- to 6-μm–thick sections were
obtained. In addition to H&E staining, murine samples were assessed
for expression of tMUC1 using TAB 004 antibody. Briefly, either
unconjugated TAB 004 antibody followed with a second step
detection with an anti-mouse HRP-conjugated secondary antibody or
the TAB 004-HRP conjugated was used. The staining procedure
includes a blocking step, incubation with primary antibody
(overnight, 4°C) and secondary antibody (1 hour), or incubation
with primary antibody conjugated with HRP (overnight, 4°C). In
both approaches, the presence of TAB 004 antibody was revealed
using DAB with a hematoxylin counterstain followed by mounting
the tissue slides. Tissue slides were then assessed by light microscopy,
and microphotographs were taken using a DP70 camera and the
Olympus Software Suite (Olympus, Waltham, MA).
Statistical Analyses
The linearity associating TAB 004 dose with the detection of
tMUC1 was assessed by linear regression. The difference between
methods in early detection time was determined by unpaired t test.
The detection of lung metastases was assessed by one-way ANOVA
followed with post hoc tests with a priori significance sets at P b .05.
Results
TheMMTMurineModelMimicsHumanBreastCancerProgression
The MMT mouse model has been described previously [10]. Briefly,
as schematized in Figure 1A, this spontaneous model of mammary tumor
progression was developed through the generation of double transgenic
mice by crossing of mice expressing human MUC1 gene [25] and mice
expressing the polyoma middle T antigen under the MMTV promoter
[26]. PyMT andMMT tumor cell lines were also developed (Figure 1A).
Over time, MMT tumors mimic the stages and cellular morphology of
human breast cancer progression (Figure 1B). Furthermore, the
biomarker tumor profiles indicate a decrease in both estrogen receptors
(ERs) and progesterone receptors (PRs), increase in Neu and Cyclin D1,
and decrease in integrin β as tumor progresses mimicking the ER−PR−
Neu+ human disease [27]. In addition, tMUC1 expression detected by
TAB 004 increases as tumors progress (Figure 1B), which makes this
model ideal for our studies. Importantly, TAB 004 does not recognize
normal mammary epithelial tissue from non–tumor-bearing control mice
(Figure 1B). The monoclonal antibody TAB 004 recognizes the
hypoglycosylated tandem repeat epitope within the STAPPVHNV
sequence of human MUC1 [20].
TAB 004 Specifically Recognizes tMUC1 In Situ by IHC, In
Vitro by Flow Cytometry, and In Vivo Following Orthotopic
Implantation of MMT Cells
PyMT and MMT cell lines were tested for tMUC1 expression in
vitro and in vivo. Compared with PyMT cells, MMT cells expressed
Figure 1. (A) HumanMUC1 expressing mammary tumor (MMT) transgenic mouse model and associated PyMT and MMT tumor cells. Briefly,
the spontaneousMMTmammary tumormodel was generated through the cross ofMUC1.tgmice [C57BL/6-Tg(MUC1)79.24Gend/Jmice] [25]
with PyMT mice [FVB/N-Tg(MMTV-PyVT)634Mul/J mice] [26]. The resulting dual transgenic female mice spontaneously develop mammary
tumors that express humanMUC1. Additionally, associated PyMT andMMT cell lines have been developed that are transgenic for the polyoma
middle T antigen and for both the polyomamiddle T antigen and humanMUC1, respectively. (B)Mammary tumor growth in theMMT transgenic
mouse model mimics human breast cancer progression. Briefly, in the spontaneous MMT mammary tumor model, the stages of hyperplasia,
adenoma, andearly and late carcinomaare identified at 6 to8, 10 to12, 18 to20, and22 to24weeksof age, respectively. Eachstage is associated
with gross pathology and cellular morphology similar to those observed in human breast cancer progression as indicated by visual observation
andH&Estaining.Moreover, expressionsof biomarkers includingERsandPRsdecreased,whereas tMUC1expression (detectedusingTAB004)
increased,withmammary tumor progression as determined using specific antibodies and IHC techniques (scale bar=200 μm). Normal C57Bl/6
mammary gland is also displayed (left) and shows no staining with TAB 004.
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staining and flow cytometry (Figure 2, A and B). Additionally, IHC
staining with TAB 004-HRP confirmed that TAB 004 only binds tothe MMT tumors but not to the PyMT tumors, further indicating
specificity to the human form of tMUC1 (Figure 2, C and D). To
determine if TAB 004 specifically localizes to the MMT tumor when
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and MMT tumor-bearing mice, and tumor progression was
successfully imaged in MMT mice over time using the IVIS system
(Figure 2, E and F). Tumor volume was monitored by caliper
measurements (Figure 2, G and H). Although both tumors grew at a
similar rate, TAB-ICG only localized to the MMT but not in the
PyMT tumors, and accumulation of TAB-ICG increased with tumor
size (Figure 2, E and F).
Next, we determined the expression of tMUC1 in the spontane-
ously arising tumors dissected from the PyMT and MMT mice. By
WB analysis, TAB 004 showed immunoreactivity with the tumor
lysates from MMT but not from PyMT tumors (Figure 2I). Lysate
from the MMT cell line was used as the positive control, and β-actin
served as the loading control. By IHC, TAB 004 stained the MMT
tumors but did not stain normal mammary epithelia or PyMT tumors
(Figure 2J). Taken together, TAB 004 showed high specificity to
human tMUC1 and did not bind to normal or mouse Muc1.Figure 2. TAB 004 detects tMUC1 in MMT cells and allows the moni
detected tMUC1 in MMT cells (B) but not in PyMT cells (A) by flow cyt
orthotopically implanted in C57Bl/6 mice, PyMT andMMT tumors grew
could be monitored using ICG-conjugated TAB 004 but only for MMT t
tMUC1 in lysates from MMT cells as well as in lysates from tumors c
not in lysates from PyMT cells (I). Furthermore, IHC analyses (J) of nor
HRP-conjugated TAB 004 detected human tMUC1 (brown stain) onlyMonitoring of Mammary Tumor Progression Is Dependent on
the Dose of TAB 004 Administered in the MMT Mice
The dose of TAB-ICG injected to monitor the presence of tumor
mass within the MMT spontaneous mammary tumor model was
assessed for doses ranging from 12.5 to 100 μg (Figure 3). As
expected, regardless of the dose, the tumor fluorescent signal peaked
at ~24 hours and decreased thereafter, as shown in the representative
IVIS images taken over time (Figure 3A). When compared with the
number of palpable tumors, the number of fluorescent tumors in
MMT mice (8-22 weeks old) with at least one tumor mass 24 hours
postinjection of TAB-ICG varied depending on the dose of
TAB-ICG administered (Figure 3B). Indeed, whereas detection
following injections of 12.5 μg or 25 μg of TAB-ICG was high,
injections of 50 μg or 100 μg of TAB-ICG were associated with lower
tumor mass detection (Figure 3B). Furthermore, analyses limited to
mice with two or more tumors (11-22 weeks old) demonstrated that
the fluorescent detection was correlated with the amount oftoring over time of MMT orthotopic tumor growth in vivo. TAB 004
ometry and IHC (C and D), respectively (scale bar = 100 μm). When
over time (as determined by caliper measurements) (G and H) and
umors (E and F). ByWB, HRP-conjugated TAB 004 detected human
ollected following orthotopic implantation of MMT tumor cells but
mal mammary gland [C57bl/6 (i), PyMT (ii) and MMT (iii, iv, v)] using
in MMT tumors (scale bar = 150 μm).
Figure 3. In vivo detection of mammary tumor masses in the MMTmice following TAB-ICG injection is dose-dependent. MMTmice (8-22
weeks old) with palpable tumors were repeatedly injected with ICG-conjugated TAB 004 (12.5, 25, 50, or 100 μg in sterile saline) and
monitored for fluorescence using the IVIS system. (A) Representative IVIS imaging of MMT mice injected with 25 μg (top) and 100 μg
(bottom) of ICG-conjugated TAB 004 taken 1, 24, and 48 hours postinjection. The fluorescent scale [from low (blue) to high (red)] indicates
the presence of fluorescence with varying intensity at different location with the mice monitored. (B) Tumor mass fluorescent detection
(% of palpable tumors) in MMT mice with at least one tumor mass 24 hours postinjection of ICG-conjugated TAB 004. As shown, the
injection of 12.5 and 25 μg of ICG-conjugated TAB 004 was associated with improved tumor detection compared with 50 and 100 μg.
Furthermore, when only mice with two or more tumors were analyzed (B, inset), the detection increased with decreasing amount of
ICG-conjugated TAB 004 injected: from 0% to 75% for 100 and 12.5 μg, respectively (r2 = 0.96, P = .019).
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TAB-ICG injected decreased, the detection using fluorescence
increased: from 0% to 75% for 100 μg and 12.5 μg, respectively
(r2 = 0.96, P = .019). Thus, all subsequent studies were conducted
with 12.5 μg of TAB-ICG.
Administration of TAB-ICG Enables Specific and Overtime
Monitoring of tMUC1-Positive Tumors in the MMT Mice
The MMT mouse model uniquely permits the investigation of
spontaneous tumor progression in an immunocompetent mouse
model [10]. In this model, tumor progression leads to multiple tumor
masses heterogeneous for both size and stages [10]. Nevertheless, the
MMT model closely mimics human breast cancer progression
[10,27]. Here, MMT and PyMT mice at 16 weeks of age bearing
multiple palpable tumors were injected with TAB-ICG. The presence
of TAB-ICG was monitored in vivo by IVIS. As shown in Figure 4A,
TAB-ICG detected multiple palpable tumor masses in MMT mice
but did not accumulate in any of the PyMT tumors (Figure 4A). The
nonspecific fluorescence around the liver of the mice was attributed to
tissue autofluorescence.
Injections of 12.5 μg of TAB-ICG allowed the overtime
monitoring of mammary tumor progression in MMT mice (10, 14,
17, and 21 weeks of age) as indicated by representative IVIS images
shown in Figure 4B. As indicated by the yellow asterisk in the
10-week-old MMT mice, we detected the tumor by flourescence, but
there were no palpable tumors at that time. As mice aged to 14 weeks,
several of those tumors that were nonpalpable became palpable as
indicated by the yellow arrows. At later ages (weeks 17 and 21), the
yellow arrows indicate palpable tumors with accumulation of the
TAB-ICG. Whereas tumor detection by palpation and fluorescence
was similar in 13-week-old and older MMT mice, tumor detection
following injection of TAB-ICG was significantly increased compared
with palpation in MMT mice 12 weeks of age or younger(Figure 4C). Moreover, comparison of physical examination (i.e.,
palpation) and TAB 004 fluorescence indicates that primary tumors
were detected significantly earlier (~3.4 weeks earlier) by fluorescence
monitoring than by physical examination (9.4 ± 0.7 weeks of age vs
12.8 ± 0.4 weeks of age, n = 9, P = .0016, Figure 4D). Thus,
TAB-ICG has the ability to detect early stages when normal MUC1 is
undergoing the molecular transformation to tMUC1 much before
any obvious palpable tumors appear.
Administration of TAB-ICG Enables Monitoring of tMUC1-
Positive Tumors Demonstrated by Ex Vivo Assessment of
Tumors Dissected from MMT Mice
To further ascertain the potential of TAB-ICG for detection of
mammary tumor masses at early onset, ex vivo analyses were
conducted. An 18-week-old MMT mouse was injected with
TAB-ICG and imaged. Figure 5A shows high fluorescent signal
corresponding to a large tumor. When dissected and imaged ex vivo,
as expected, a very strong fluorescent signal was seen corresponding to
the largest tumor mass, but weak fluorescent signal was also noted in
the rest of the mammary fat pads (Figure 5B), indicating that these
mammary glands were not normal but had transformed to express low
levels of tMUC1. Thus, when mammary fat pads from 8- to
10-week-old MMT mice were assessed following TAB-ICG
injection, we once again detected low fluorescent signal in some of
the mammary fat pads (Figure 5C) indicating the presence of tMUC1
at very early stages of cancer progression. H&E staining confirmed
and highlighted the presence of hyperplasia in those fluorescing
mammary fat pads (Figure 5E (ii)), whereas the nonfluorescing
mammary fat padwas composedmostly of normal tissue (Figure 5E (i)).
Ex vivo imaging following TAB-ICG administration of tumors
and mammary fat pad dissected from 18-week-old MMT mice
bearing multiple tumors revealed that the amount of fluorescent
signal distinguishes between tumor masses and hyperplastic
Figure 4. Early detection of primary mammary tumors in the MMT mice following TBA-ICG injection. (A) ICG-conjugated TAB 004
detected tMUC1+ tumors in MMT mice only but not in PyMT mice, where tumors were not fluorescent (only nonspecific liver
fluorescence was observed). (B) Representative IVIS images of tumormasses detected inMMTmice 10, 14, 17, and 21weeks of age. The
presence of tumor mass was monitored over time in MMT mice aged 9 to 23 weeks. Both physical examination (palpation) and
fluorescence monitoring using the IVIS system 24 hours postinjection of ICG-TAB 004 were collected over time. Yellow asterisks and
yellow arrows indicate the presence of nonpalpable and palpable tumors, respectively, whereas red arrows note the presence of
nonfluorescent palpable tumor mass essentially in older mice. (C) Whereas tumor detection by palpation and fluorescence was similar in
13-week-old and older MMT mice, tumor detection following injection of ICG-conjugated TAB 004 associated with IVIS system was
increased compared with palpation in MMT mice 12 weeks old and younger. (D) Early detection indicates that primary tumors are
detected significantly earlier by fluorescence monitoring than by physical examination (9.4 ± 0.7 weeks of age vs 12.8 ± 0.4 weeks of
age, n = 9, P = .0016).
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extensive presence of tumor in the strongly fluorescing tumor in
the 18-week-old MMT mice (Figure 5F).
Administration of TAB-ICG Allows Monitoring of tMUC1-
Positive Lung Metastases Demonstrated by Ex Vivo Assessment
of Fluorescent Signal in the Lungs of MMT Mice
Whether TAB 004 could detect the presence of metastases in the
MMT mice was assessed ex vivo following in vivo administration of
TAB-ICG. The fluorescent signal in several organs dissected from
MMT mice at various ages (b16, 16-20, and N20 weeks of age) was
determined using the IVIS system. No increase in fluorescence was
observed in the liver, spleens, and brain of MMT mice versus normal
C57BL/6 organs (data not shown). However, fluorescent signal in the
lungs was significantly higher than control mouse lung, and the signal
exponentially increased with the age of MMTmice (Figure 6A) [1.71 ×
106 ± 0.11 × 106, 2.21 × 106 ± 0.08 × 106, and 2.10 × 106 ± 0.05 × 106
for 8- to 11- (n = 7), 16- to 18- (n = 6), and 19- to 22- (n = 7) week-old
MMT mice, respectively, P b .05]. This increase in fluorescent
signal with age suggests micrometastasis in the lungs. Indeed, as inthe PyMT model, MMT mice develop metastases mainly in the lungs
[10]. The presence of micrometastases was confirmed in these MMT
mice following H&E staining of the lung (Figure 6B). Representative
H&E shows clear lesion in the MMT lung [Figure 6B (ii)] versus no
lesion in the control lung [Figure 6B (i)].
Discussion
We have demonstrated the specificity and sensitivity of TAB 004, an
antibody against the hypoglycosylated form of human MUC1
(tMUC1). TAB 004 conjugated to indocyanine green (TAB-ICG)
enables the in vivo monitoring of primary mammary tumor
progression and metastasis in the MMT mice. The results highlight
the early detection of neoplastic transformation as well as detect
micrometastases in the lungs.
In contrast to PyMT mice, MMT mice have been genetically
engineered to express human tMUC1, whereas the former express the
murine form of hypoglycosylated Muc1 [10]. Those models,
although significantly more aggressive than generally observed in
human breast cancer progression, appropriately mimic the cancer
progression from hyperplasia to adenocarcinoma and metastasis in an
Figure 5. Ex vivo assessment of mammary gland tumors from MMT mice post TAB-ICG injection. Representative mouse assessed for
fluorescence using IVIS system following injection of 12.5 μg of TAB 004 conjugated with ICG in vivo (A) and the corresponding ex vivo
posteuthanasia mammary fat pads assessed using the same system (B). Entire mammary ridges (left and right) isolated from a
10-week-old (C) and an 18-week-old (D) MMT mouse are displayed, and the presence within the mammary pad (MP) of tumor mass (T) is
noted. Furthermore, when assessed following H&E staining (scale bar = 100 μm), MP from the 10-week-old mouse presented mostly
normal mammary tissues [E (i)]. However, even that early, hyperplasia was observed in a few areas of the MP [arrow, E (ii)]. In older mice
(~18 weeks old), whether PyMT or MMT, the presence of tumor was extensive (F).
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models to investigate in vivo tumor detection.
TAB 004 specifically targets the transformed MUC1 protein with
minimal immunoreactivity with the normal MUC1. This increased
specificity of TAB 004 to tMUC1 expressed in the spontaneously
arising mammary gland tumors in MMT mice is a novel finding and
may allow earlier diagnosis of breast tumors. The specificity of TAB
004 was further demonstrated in MMT cell lines by IHC, WB, and
flow cytometry. Extensive clinical research indicates that there are
several molecular classifications of breast tumors based upon the
expression of specific receptors (ER, PR, Her2/neu) and the cell
origin (basal versus luminal). These subtypes are associated withsignificant differences in patients’ survival [28–30]. For instance,
triple-negative breast cancers are more aggressive and difficult to treat.
Those observations led to the generation of multiparameter tests (e.g.,
Oncotype DX, 21-gene recurrence score) to support therapeutic
decision [31,32]. Although those tests have proven beneficial
especially in determining specific treatment courses for a given
tumor type [33,34], the tests are not useful for early diagnosis. The
clinical use of TAB 004 may be in the space of aiding diagnosis early
and accurately especially given that mammograms fail in women with
dense breast 50% of the time and overall misses 25% of the tumors.
Furthermore, mammograms have high false-positive rates as N80% of
biopsies post suspicious mammograms turn out to be benign. Indeed,
Figure 6.Detection of lungmetastases in the MMTmice post TAB-ICG injection. (A) The presence of fluorescence [expressed as arbitrary
unit (AU)] associated with the injection of ICG-conjugated TAB 004 was measured ex vivo on isolated lungs posteuthanasia using the IVIS
system. Compared to control (Ctrl) lungs (lungs isolated from a noninjected MMT mouse), detected fluorescence increased with age in
MMTmice [5.99 × 106 ± 1.5 × 106, 11.73 × 106 ± 0.8 × 106, and 13.1 × 106 ± 2.23 × 106 for MMTmice b16 (n= 7), 16-20 (n= 6), and
N20 (n= 7) weeks old, respectively; *P b .05]. (B) Normal lung (i) and micrometastasis (ii) in the lungs of a 16- to 17-week-old MMT female
mouse stained with H&E (scale bar = 100 μm).
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that 95% of BCs express tMUC1, as detected by TAB 004 staining
and IHC, regardless of the tumor subtype and density of the breast
tissue (manuscript in preparation).
Although most approaches (physical, imaging, blood tests, and
combination thereof) diagnose with significant accuracy the presence
of advanced breast cancer, the earlier stages remain much more
difficult to detect reliably [4,7,35,36]. Indeed, for those early stages
including atypical hyperplasia and ductal carcinoma in situ,
mammographic examination is associated with a high false-positive
rate [6]. Similarly, the determination of circulatory CEA and or
CA-15-3 antigen lacks the specificity and sensitivity in individuals
with early disease, although they may be of benefit in monitoring
metastasis and disease recurrence [37]. Multiple studies have
demonstrated improved detection when using ultrasounds and
magnetic resonance imaging (MRI) [7,38], although those ap-
proaches are mostly used to further assess suspicious mass
abnormalities detected during mammography [4,38] as opposed to
screening. The numbers of false-positive and to a lesser extent of
false-negative cases highlight the potential of molecularly targeted
imaging, especially to detect early stages of the disease and possibly
micrometastasis.
Moreover, as tMUC1 is present inmultiple epithelial cancers including
colon carcinoma, ovarian cancer, and pancreatic cancer, TAB 004 may
serve as a detecting and monitoring tool for multiple cancers. Already,
preclinical and clinical observations have demonstrated the specificity of
TAB 004 antibody toward tMUC1 antigen in pancreatic cancer [20].
In vivo, TAB-ICG detected primary tumors generally before they
were palpable in the MMT model. The early detection of
nonpalpable tumors by TAB-ICG including hyperplasia forms
proof of principle of the potential use of this antibody in the clinic
in conjunction with other imaging modalities. For example,conjugated with radioactive imaging agents, TAB 004 could greatly
improve the reliability of early breast cancer diagnosis when used in
conjunction with computed tomography or MRI [39–43].
Interestingly, ex vivo imaging and H&E staining provide evidence
that TAB-ICG enabled detection of lung metastases as early as 16
weeks of age in MMT mice (Figure 6). Thus, we suggest that TAB
004 conjugated to radioactive material such as technetium (99m)
along with MRI and computed tomography scan may provide
improved monitoring of the development of distant metastases in
patients with breast cancer.
Clinically, although early detection is the key in breast cancer
treatment, standard mammography generates a high number of false
negatives, especially in women with dense breasts [4,6,7,44–46]. For
those patients, additional examinations and imaging such as
ultrasounds and MRI may be conducted. Mammography also
generates false positive and biopsies, which in many cases are
unwarranted [4,47]. Overall, two-dimensional mammograms have
been deemed of limited use in individuals with dense breast tissues
(40% of the women) [6–8] because for those patients, the
mammograms are often difficult to interpret [44,48].
In summary, our investigations demonstrate the specificity of TAB
004 antibody against hypoglycosylated human MUC1 and its
potential in early detection of transformed mammary epithelial cells
and micrometastasis. Based on this proof of principle, we suggest that
TAB 004 conjugated with contrasting agents or radioisotopes used in
current clinical imaging protocols will allow both early and accurate
detection and monitoring of breast cancer, even in women with dense
breast tissue. We further propose that because tMUC1 is present in
most epithelium-derived cancers, TAB 004 likely may be beneficial in
the detection and monitoring of multiple cancers.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.05.001.
304 Breast Cancer Detection Using a Specific Antibody to MUC1 Moore et al. Translational Oncology Vol. 9, No. 4, 2016Acknowledgements
The authors acknowledge the support of the Vivarium staff andDr. C.Williams, DVM, for the excellent animal care and imaging expertise
provided. The authors also acknowledge Mallory B. Korman (Research
Histology Confocal Core Lab) at Carolinas Medical Center for the
histological embedding and sectioning of murine samples.References
[1] CamponeM, Valo I, Jezequel P, MoreauM, Boissard A, Campion L, Loussouarn
D, Verriele V, Coqueret O, and Guette C (2015). Prediction of recurrence and
survival for triple-negative breast cancer by a protein signature in tissue samples.
Mol Cell Proteomics 14, 2936–2946.
[2] Ward EM, DeSantis CE, Lin CC, Kramer JL, Jemal A, Kohler B, Brawley OW,
and Gansler T (2015). Cancer statistics: breast cancer in situ. CA Cancer J Clin
65, 481–495.
[3] DeSantis C, Ma J, Bryan L, and Jemal A (2014). Breast cancer statistics, 2013.
CA Cancer J Clin 64, 52–62.
[4] Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YT,
Walter LC, Church TR, Flowers CR, and LaMonte SJ, et al (2015). Breast
cancer screening for women at average risk: 2015 guideline update from the
American Cancer Society. JAMA 314, 1599–1614.
[5] Gilbert FJ, Tucker L, Gillan MG,Willsher P, Cooke J, Duncan KA, Michell MJ,
Dobson HM, Lim YY, and Purushothaman H, et al (2015). The TOMMY trial:
a comparison of TOMosynthesis with digital MammographY in the UK NHS
Breast Screening Programme—a multicentre retrospective reading study
comparing the diagnostic performance of digital breast tomosynthesis and digital
mammography with digital mammography alone. Health Technol Assess 19,
1–136 [i-xxv].
[6] Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, and
Miglioretti DL (2015). Identifying women with dense breasts at high risk for
interval cancer: a cohort study. Ann Intern Med 162, 673–681.
[7] Scheel JR, Lee JM, Sprague BL, Lee CI, and Lehman CD (2015). Screening
ultrasound as an adjunct to mammography in women with mammographically
dense breasts. Am J Obstet Gynecol 212, 9–17.
[8] Moshina N, Ursin G, Hoff SR, Akslen LA, Roman M, Sebuodegard S, and
Hofvind S (2015). Mammographic density and histopathologic characteristics of
screen-detected tumors in the Norwegian Breast Cancer Screening Program. Acta
Radiol Open 4. http://dx.doi.org/10.1177/2058460115604340.
[9] Beatson RE, Taylor-Papadimitriou J, and Burchell JM (2010). MUC1
immunotherapy. Immunotherapy 2, 305–327.
[10] Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J,
Agrawal B, Longenecker BM, and Gendler SJ (2003). Mucin 1-specific
immunotherapy in a mouse model of spontaneous breast cancer. J
Immunother 26, 47–62.
[11] Ideo H, Hinoda Y, Sakai K, Hoshi I, Yamamoto S, Oka M, Maeda K, Maeda N,
Hazama S, and Amano J, et al (2015). Expression of mucin 1 possessing a 3'-sulfated
core1 in recurrent and metastatic breast cancer. Int J Cancer 137, 1652–1660.
[12] Siroy A, Abdul-Karim FW, Miedler J, Fong N, Fu P, Gilmore H, and Baar J
(2013). MUC1 is expressed at high frequency in early-stage basal-like
triple-negative breast cancer. Hum Pathol 44, 2159–2166.
[13] Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Odum N, Mandel U,
Clausen H, Pedersen AE, and Wandall HH (2013). Aberrantly glycosylated
MUC1 is expressed on the surface of breast cancer cells and a target for
antibody-dependent cell-mediated cytotoxicity. Glycoconj J 30, 227–236.
[14] Mommers EC, Leonhart AM, von Mensdorff-Pouilly S, Schol DJ, Hilgers J,
Meijer CJ, Baak JP, and van Diest PJ (1999). Aberrant expression of MUC1
mucin in ductal hyperplasia and ductal carcinoma In situ of the breast. Int J
Cancer 84, 466–469.
[15] Alam M, Rajabi H, Ahmad R, Jin C, and Kufe D (2014). Targeting the
MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.
Oncotarget 5, 2622–2634.
[16] Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, and
Kufe D (2015). Characterization of the MUC1-C cytoplasmic domain as a cancer
target. PLoS One 10, e0135156. http://dx.doi.org/10.1371/journal.pone.0135156.
[17] Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, and Stieber P (2015).
Serum HER2 in combination with CA 15-3 as a parameter for prognosis in
patients with early breast cancer. Clin Chim Acta 440, 16–22.[18] Incoronato M, Mirabelli P, Catalano O, Aiello M, Parente C, Soricelli A, and
Nicolai E (2014). CA15-3 is a useful serum tumor marker for diagnostic
integration of hybrid positron emission tomography with integrated computed
tomography during follow-up of breast cancer patients. BMC Cancer 14, 356.
http://dx.doi.org/10.1186/1471-2407-14-356.
[19] Grzywa R, Lupicka-Slowik A, Walczak M, Idzi M, Bobrek K, Boivin S, Gawel A,
Stefaniak T, Oleksyszyn J, and Sienczyk M (2014). Highly sensitive detection of
cancer antigen 15-3 using novel avian IgY antibodies. ALTEX 31, 43–52.
[20] Curry JM, Thompson KJ, Rao SG, Besmer DM,Murphy AM, Grdzelishvili VZ,
Ahrens WA, McKillop IH, Sindram D, and Iannitti DA, et al (2013). The use of
a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in
mice and patients with pancreatic cancer. J Surg Oncol 107, 713–722.
[21] Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler
SJ, Kufe D, and Gong J (2003). Immunotherapy of spontaneous mammary
carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Immunology 109, 300–307.
[22] Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E,
Shanmugam K, Lee YY, and Hwang SI, et al (2011). MUC1 enhances
invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal
transition. Oncogene 30, 1449–1459.
[23] Nath S, Roy LD, Grover P, Rao S, and Mukherjee P (2015). Mucin 1 regulates
Cox-2 gene in pancreatic cancer. Pancreas 44, 909–917.
[24] HardestyDA,ThindH,Zabramski JM,SpetzlerRF, andNakaji P (2014). Safety, efficacy,
and cost of intraoperative indocyanine green angiography compared to intraoperative
catheter angiography in cerebral aneurysm surgery. J Clin Neurosci 21, 1377–1382.
[25] Rowse GJ, Ritland SR, and Gendler SJ (1998). Genetic modulation of neu
proto-oncogene-induced mammary tumorigenesis. Cancer Res 58, 2675–2679.
[26] Guy CT, Cardiff RD, and Muller WJ (1992). Induction of mammary tumors by
expression of polyomavirus middle T oncogene: a transgenic mouse model for
metastatic disease. Mol Cell Biol 12, 954–961.
[27] Fluck MM and Schaffhausen BS (2009). Lessons in signaling and tumorigenesis
from polyomavirus middle T antigen. Microbiol Mol Biol Rev 73, 542–563.
[28] Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, and Akslen LA, et al (2000). Molecular portraits of human
breast tumours. Nature 406, 747–752.
[29] Sorlie T (2007). Molecular classification of breast tumors: toward improved
diagnostics and treatments. Methods Mol Biol 360, 91–114.
[30] Norum JH, Andersen K, and Sorlie T (2014). Lessons learned from the intrinsic
subtypes of breast cancer in the quest for precision therapy. Br J Surg 101, 925–938.
[31] Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, Hofstatter
EW,Abu-KhalafM,GrossCP, andEvans SB (2016). Influence of a 21-gene recurrence
score assay on chemotherapy delivery in breast cancer. Clin Breast Cancer 16, 59–62.
[32] Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M,
Soussan-Gutman L, Merling S, Svedman C, Rizel S, and Lieberman N
(2013). The impact of the 21-gene Recurrence Score assay on clinical
decision-making in node-positive (up to 3 positive nodes) estrogen receptor–
positive breast cancer patients. Breast Cancer Res Treat 140, 83–92.
[33] Cobain EF and Hayes DF (2015). Indications for prognostic gene expression
profiling in early breast cancer. Curr Treat Options Oncol 16, 23. http:
//dx.doi.org/10.1007/s11864-015-0340-x.
[34] McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, and
Kerin MJ (2014). The impact of Oncotype DX testing on breast cancer
management and chemotherapy prescribing patterns in a tertiary referral centre.
Eur J Cancer 50, 2763–2770.
[35] Retsky M, Demicheli R, and Hrushesky W (2003). Breast cancer screening:
controversies and future directions. Curr Opin Obstet Gynecol 15, 1–8.
[36] Nicolini A, Carpi A, and Tarro G (2006). Biomolecular markers of breast cancer.
Front Biosci 11, 1818–1843.
[37] Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I, and
Di Gioia D (2015). Diagnostic efficacy of CA 15-3 and CEA in the early
detection of metastatic breast cancer—a retrospective analysis of kinetics on 743
breast cancer patients. Clin Chim Acta 448, 228–231.
[38] Debald M, Abramian A, Nemes L, Dobler M, Kaiser C, Keyver-Paik MD,
Leutner C, Holler T, Braun M, and Kuhl C, et al (2015). Who may benefit from
preoperative breast MRI? A single-center analysis of 1102 consecutive patients
with primary breast cancer. Breast Cancer Res Treat 153, 531–537.
[39] Goldenberg DM and Nabi HA (1999). Breast cancer imaging with radiolabeled
antibodies. Semin Nucl Med 29, 41–48.
[40] Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, and Sevick-Muraca
EM (2007). Dual-labeled trastuzumab-based imaging agent for the detection of
Translational Oncology Vol. 9, No. 4, 2016 Breast Cancer Detection Using a Specific Antibody to MUC1 Moore et al. 305human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl
Med 48, 1501–1510.
[41] Lutje S, Rijpkema M, Franssen GM, Fracasso G, Helfrich W, Eek A, Oyen WJ,
Colombatti M, and Boerman OC (2014). Dual-modality image-guided surgery
of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal
antibody. J Nucl Med 55, 995–1001.
[42] Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA,
Boerman OC, de Jong M, and van Weerden WM (2015). A novel
(1)(1)(1)In-labeled anti-prostate-specific membrane antigen nanobody for
targeted SPECT/CT imaging of prostate cancer. J Nucl Med 56, 1094–1099.
[43] Signore A, Capriotti G, Chianelli M, Bonanno E, Galli F, Catalano C, Quintero
AM, De Toma G, Manfrini S, and Pozzilli P (2015). Detection of insulitis by
pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with
LADA (Action LADA 10). Diabetes Care 38, 652–658.[44] Chetlen A, Mack J, and Chan T (2016). Breast cancer screening controversies:
who, when, why, and how? Clin Imaging 40, 279–282.
[45] Rosso A, Lang K, Petersson IF, and Zackrisson S (2015). Factors affecting recall
rate and false positive fraction in breast cancer screening with breast
tomosynthesis—a statistical approach. Breast 24, 680–686.
[46] Rhodes DJ, Radecki Breitkopf C, Ziegenfuss JY, Jenkins SM, and Vachon CM
(2015). Awareness of breast density and its impact on breast cancer detection and
risk. J Clin Oncol 33, 1143–1150.
[47] Kemp Jacobsen K, O'Meara ES, Key D, D SM Buist D, Kerlikowske K, Vejborg
I, Sprague BL, Lynge E, and von Euler-Chelpin M (2015). Comparing sensitivity
and specificity of screening mammography in the United States and Denmark.
Int J Cancer 137, 2198–2207.
[48] Slanetz PJ, Freer PE, and Birdwell RL (2015). Breast-density legislation—
practical considerations. N Engl J Med 372, 593–595.
